GLP1R and diabetes mellitus: Access to GLP-1 medications in the US remains uneven, as they are often not reimbursed by Medicare or most state Medicaid programs for weight loss alone.54 Disparities in access persist even among those with diabetes.55 Guidelines also exclude individuals starting ART at normal or overweight levels, as the simultaneous initiation of GLP-1 medications and ART is complicated by limited evidence, potential drug-drug interactions, and side effects that could impact ART adherence.